Cortical blindness and seizures possibly related to cisplatin, vinblastine, and bleomycin treatment of ovarian dysgerminoma.

Abstract

Ovarian dysgerminoma is the most common ovarian malignancy in young women. Conservative treatment is indicated in the reproductive-age woman who wishes to preserve childbearing capacity. This case report describes a patient with ovarian dysgerminoma who underwent chemotherapy with a cisplatin-vinblastine-bleomycin regimen that resulted in serious toxic complications--including cortical blindness and seizures--that were transient in nature. Although current chemotherapy regimens have dramatically improved the overall survival of women with germ-cell tumors, there are toxic complications such as those demonstrated in this report, and toxicity must be balanced against presumed benefit.

• Authors: D C Young, A Mitchell, J Kessler, J E Christman
• Journal: The Journal of the American Osteopathic Association (J Am Osteopath Assoc) Vol. 93 Issue 4 Pg. 502-4, 507 (Apr 1993) ISSN: 0098-6151 [Print] United States
• PMID: 7683015 (Publication Type: Case Reports, Journal Article)

Chemical References

• Bleomycin
• Vinblastine
• Cisplatin

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Bleomycin (adverse effects)
• Blindness (chemically induced)
• Cisplatin (adverse effects)
• Dysgerminoma (drug therapy)
• Female
• Humans
• Ovarian Neoplasms (drug therapy)
• Seizures (chemically induced)
• Vinblastine (adverse effects)